LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC).
Saved in:
| Title: | LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). |
|---|---|
| Authors: | Moore, K.N.1 (AUTHOR), Bookman, M.2 (AUTHOR), Sehouli, J.3 (AUTHOR), Miller, A.4 (AUTHOR), Anderson, C.5 (AUTHOR), Scambia, G.6 (AUTHOR), Myers, T.7 (AUTHOR), Taskiran, C.8 (AUTHOR), Robison, K.9 (AUTHOR), Maenpaa, J.10 (AUTHOR), Willmott, L.J.11 (AUTHOR), Colombo, N.12 (AUTHOR), Thomes-Pepin, J.13 (AUTHOR), Gold, M.A.14 (AUTHOR), Aghajanian, C.15 (AUTHOR), Wu, F.16 (AUTHOR), Molinero, L.17 (AUTHOR), Khor, V.18 (AUTHOR), Lin, Y.G.18 (AUTHOR), Pignata, S.19 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS1161-S1162. 2p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 152696705 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Moore%2C+K%2EN%2E%22">Moore, K.N.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bookman%2C+M%2E%22">Bookman, M.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sehouli%2C+J%2E%22">Sehouli, J.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Miller%2C+A%2E%22">Miller, A.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Anderson%2C+C%2E%22">Anderson, C.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Scambia%2C+G%2E%22">Scambia, G.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Myers%2C+T%2E%22">Myers, T.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Taskiran%2C+C%2E%22">Taskiran, C.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Robison%2C+K%2E%22">Robison, K.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Maenpaa%2C+J%2E%22">Maenpaa, J.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Willmott%2C+L%2EJ%2E%22">Willmott, L.J.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Colombo%2C+N%2E%22">Colombo, N.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Thomes-Pepin%2C+J%2E%22">Thomes-Pepin, J.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gold%2C+M%2EA%2E%22">Gold, M.A.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Aghajanian%2C+C%2E%22">Aghajanian, C.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wu%2C+F%2E%22">Wu, F.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Molinero%2C+L%2E%22">Molinero, L.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Khor%2C+V%2E%22">Khor, V.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lin%2C+Y%2EG%2E%22">Lin, Y.G.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pignata%2C+S%2E%22">Pignata, S.</searchLink><relatesTo>19</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2020 Supplement 4, Vol. 31, pS1161-S1162. 2p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=152696705 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2020.08.2261 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 2 StartPage: S1161 Titles: – TitleFull: LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Moore, K.N. – PersonEntity: Name: NameFull: Bookman, M. – PersonEntity: Name: NameFull: Sehouli, J. – PersonEntity: Name: NameFull: Miller, A. – PersonEntity: Name: NameFull: Anderson, C. – PersonEntity: Name: NameFull: Scambia, G. – PersonEntity: Name: NameFull: Myers, T. – PersonEntity: Name: NameFull: Taskiran, C. – PersonEntity: Name: NameFull: Robison, K. – PersonEntity: Name: NameFull: Maenpaa, J. – PersonEntity: Name: NameFull: Willmott, L.J. – PersonEntity: Name: NameFull: Colombo, N. – PersonEntity: Name: NameFull: Thomes-Pepin, J. – PersonEntity: Name: NameFull: Gold, M.A. – PersonEntity: Name: NameFull: Aghajanian, C. – PersonEntity: Name: NameFull: Wu, F. – PersonEntity: Name: NameFull: Molinero, L. – PersonEntity: Name: NameFull: Khor, V. – PersonEntity: Name: NameFull: Lin, Y.G. – PersonEntity: Name: NameFull: Pignata, S. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2020 Supplement 4 Type: published Y: 2020 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 31 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
